Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Potential benefits include: Appetite suppression Increased fullness after meals Reduced food cravings Sustainable weight-loss support Tirzepatide Tirzepatide works on both GLP-1 and GIP receptors
These symptoms can be non-specific and may be mistakenly attributed to gastrointestinal side effects commonly associated with GLP-1 agonists, such as nausea or dyspepsia
Entry point for public reimbursement Using the reduced off-patent price as a strong argument for increased access, Canada could become the first market with wide-scale reimbursement of existing primary care medicines, including GLP-1s for diabetes, to designate off-patent semaglutide as the first-line anti-obesity medication (AOM)
The TRIUMPH-4 trial reported percent body weight changes of -26.4% at the 9mg dose and -28.7% at the 12mg dose, compared to just -2.1% with placebo
